Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Aptorum Group Limited (Nasdaq: APM) announced that an interview with President Mr. Darren Lui will air on The RedChip Money Report on Bloomberg Network on July 10 at 7 p.m. U.S. Eastern. This program reaches 73 million homes in the U.S. The company focuses on developing therapeutics for unmet medical needs, particularly in oncology and infectious diseases. Additionally, Aptorum is enhancing its pipeline through new drug discovery platforms and co-developing rapid pathogen diagnostics with Accelerate Technologies.
- Interview with President Darren Lui on Bloomberg Network enhances visibility for Aptorum Group.
- Focus on unmet medical needs in oncology and infectious diseases shows strong market potential.
- Development of drug discovery platforms and rapid pathogen diagnostics indicates innovation and growth potential.
- None.
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with President and Executive Director Mr. Darren Lui will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, July 10 at 7 p.m. U.S. Eastern across the United States. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. U.S. Eastern in 73M homes.
To view the interview segment, please visit https://youtu.be/6gOVJ4xFUWs
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research. For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020.
As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.
This press release is provided “as is” without any representation or warranty of any kind.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005015/en/
FAQ
When will the interview with Darren Lui air?
What is Aptorum Group Limited's focus area?
Where can I watch the interview with Darren Lui?
What is the stock symbol for Aptorum Group Limited?
What technologies is Aptorum Group developing?
